Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Nicolini

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
European Journal of Nuclear Medicine and Molecular Imaging|June 27, 2020
Clinical value of negative <sup>68</sup>Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patientsM Celli, U De Giorgi, P Caroli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2015
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumorsL Bodei, M Kidd, I M Modlin, et al.
ESMO Open|June 17, 2021
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trialsS Severi, A Bongiovanni, M Ferrara, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
European Journal of Nuclear Medicine and Molecular Imaging|June 27, 2020
Clinical value of negative <sup>68</sup>Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patientsM Celli, U De Giorgi, P Caroli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2015
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumorsL Bodei, M Kidd, I M Modlin, et al.
ESMO Open|June 17, 2021
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trialsS Severi, A Bongiovanni, M Ferrara, et al.
Pageof 2